Company: ZVRA
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001628280-25-039967
Chunk: 46

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 46
---
 shares issued and 53,670,709 shares outstanding as of December 31, 20246 5 Additional paid-in capital564,316 555,302 Treasury stock, at cost(10,983)(10,983)Accumulated deficit(433,681)(505,289)Accumulated other comprehensive (loss) income(2,428)631 Total stockholders' equity117,230 39,666 Total liabilities and stockholders' equity$256,277 $178,127 

See accompanying notes to unaudited condensed consolidated financial statements.

4

Table of Contents

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

Three months ended June 30,Six months ended June 30,2025202420252024Revenue, net$25,881 $4,449 $46,282 $7,874 Cost of product revenue (excluding $1,616 and $1,546 in intangible asset amortization for the three months ended June 30, 2025, and 2024, respectively, and $3,231 and $3,074 in intangible asset amortization for the six months ended June 30, 2025, and 2024, respectively, shown separately below)12,379 3,573 13,724 3,748 Intangible asset amortization1,616 1,546 3,231 3,074 Impairment of intangible assets58,710 — 58,710 — Operating expenses:Research and development3,433 10,521 6,691 22,798 Selling, general and administrative20,782 12,604 40,327 22,535 Total operating expenses24,215 23,125 47,018 45,333 Loss from operations(71,039)(23,795)(76,401)(44,281)Other income (expense):Gain on sale of PRV148,325 — 148,325 — Interest expense(2,009)(2,110)(3,978)(2,845)Fair value adjustment related to warrant and CVR liability(747)5,779 4,127 9,406 Fair value adjustment related to investments(2)1 (5)(26)Interest